BCL-2/BCL-xL dual inhibition and apoptotic dependence in myeloid neoplasms
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-01 — Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.: Phase I dose-escalation of navitoclax + venetoclax + decitabine in high-risk myeloid neoplasms (including AP/BP-MF and MDS/MPN overlap) established tolerability, defined an RP2D, and reported a 60% objective response rate, supporting the clinical feasibility of dual BCL-2/BCL-xL blockade with hypomethylating agent backbone. (novelty: 3)
Open questions
Related
Contributing findings
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.
01-aug-2026
novelty 3
per-area 3
strengthens